Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine

HOLZKIRCHEN, Germany, Dec. 8, 2017 /PRNewswire/ — Sandoz, a division of Novartis and the global leader in biosimilars, today announced data demonstrating the pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity of proposed biosimilar pegfilgrastim as compared to the…